Andy
Retired committee member
Appears to be some kind of foreword to the April and May issues of Clinical Therapeutics which will feature a number of articles on ME/CFS.
Open access at https://www.clinicaltherapeutics.com/article/S0149-2918(19)30116-X/fulltextChronic fatigue syndrome (CFS), later named myalgic encephalomyelitis (ME), is characterized primarily by severe, long-lasting fatigue along with dysfunctional homeostasis, especially temperature dysregulation.1, 2 The term fatigue was apparently first used in the 1550s in France as fatiguer (to tire) from the Latin term fatigauts. However, the concept of fatigue (κόπος) was used in 400 BC by Hippocrates and later in 170 AD by Galen.3 In fact, Galen was the first to write that “severe fatigue will stir up fever,” a possible preamble to the dysregulated temperature characterizing ME/CFS.
Scientists have struggled without much success to identify the reason(s) for the severe fatigue in ME/CFS. The obvious presence of subgroups4 has hampered the identification of objective biomarkers and the development of effective drugs. Studies on viral etiology,5 mitochondrial or metabolic dysfunction,6 and fatigue-producing cytokines7 have been inconclusive when appropriate sedentary controls were included. Recent studies focused on immune dysregulation,8, 9 activation of microglia in the prefrontal cortex of a rat model of fatigue,10 and localized inflammation in the hypothalamus.